Burkholderia cepacia complex: Difference between revisions
From IDWiki
Burkholderia cepacia complex
mNo edit summary |
(→) |
||
| Line 6: | Line 6: | ||
** [[Burkholderia multivorans]] (genomovar II) |
** [[Burkholderia multivorans]] (genomovar II) |
||
** [[Burkholderia dolosa]] (genomovar VI) |
** [[Burkholderia dolosa]] (genomovar VI) |
||
| + | * Environmental organism |
||
* Multiple mechanisms of resistance: |
* Multiple mechanisms of resistance: |
||
** β-lactamases |
** β-lactamases |
||
| Line 16: | Line 17: | ||
* Opportunistic lung infections, primarily of [[cystic fibrosis]] and [[lung transplant]] patients |
* Opportunistic lung infections, primarily of [[cystic fibrosis]] and [[lung transplant]] patients |
||
* Colonizes the lungs of patients with [[cystic fibrosis]] and portends a poor prognosis |
* Colonizes the lungs of patients with [[cystic fibrosis]] and portends a poor prognosis |
||
| + | * Occasionally causes nosocomial outbreaks traced back to aqueous pharmaceutical products |
||
== Management == |
== Management == |
||
Revision as of 12:44, 6 February 2023
Background
- Gram-negative bacillus
- Classified into nine genomovars (phenotypically similar but genotypically distinct)
- Burkholderia cenocepacia (genomovar III)
- Burkholderia multivorans (genomovar II)
- Burkholderia dolosa (genomovar VI)
- Environmental organism
- Multiple mechanisms of resistance:
- β-lactamases
- RND efflux pumps
- Altered LPS conferring polymixin resistance
- Gyrase mutations conferring fluoroquinolone resistance
Clinical Manifestations
- Opportunistic lung infections, primarily of cystic fibrosis and lung transplant patients
- Colonizes the lungs of patients with cystic fibrosis and portends a poor prognosis
- Occasionally causes nosocomial outbreaks traced back to aqueous pharmaceutical products
Management
- Should be guided by antimicrobial susceptibility testing
- Antibiotic options include:
- TMP-SMX (preferred, if susceptible)
- Ceftazidime and ceftazidime-avibactam
- Meropenem and imipenem
- Minocycline
